References
- Ovarian Cancer Statistics. How common is ovarian cancer. Internet] [cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html.
- Ovarian Cancer Survival Rates. Ovarian cancer prognosis. Internet] [cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html.
- Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics. CA Cancer J Clin. 2018;68(4).
- Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016;27(3). 10.3802/jgo.2016.27.e25
- Rojas V, Hirshfield KM, Ganesan S, et al. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int J Mol Sci. 2016;17(12):2113.
- Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type i and Type II. Biomed Res Int. 2014;2014:1–11.
- Dion L, Carton I, Jaillard S, et al. The landscape and therapeutic implications of molecular profiles in epithelial ovarian cancer. J Clin Med. 2020;9(7):2239.
- Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer pubmed. N Engl J Med. 2003;348(3).
- Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12.
- Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007;104.
- Wang P, Chen Y, Wang C. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front Oncol. 2021;11.
- Wang ZC, Birkbak NJ, Culhane AC, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res off J Am Assoc Cancer Res. 2012;18.
- Freimund AE, Beach JA, Christie EL, et al. Mechanisms of drug resistance in high-grade serous ovarian cancer pubmed. Hematol Oncol Clin North Am. 2018;32(6).
- Yang Y, Yang Y, Yang J, et al. Tumor microenvironment in ovarian cancer: function and therapeutic strategy. Front Cell Dev Biol. 2020;8.
- Rodriguez GM, Galpin KJC, McCloskey CW, et al. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers (Basel). 2018;10(8):242.
- Launonen L, Lyytikäinen, Casado N, et al. Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Nat Commun. 2022;13(1):1–14.
- Schoutrop E, Moyano-Galceran L, Lheureux S, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86:207–223.
- Maiorano BA, Maiorano MFP, Lorusso D, et al. Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives. Cancers (Basel). 2021;13(17):4438.
- Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol. 2021;10.
- Revythis A, Limbu A, Mikropoulos C, et al. Recent Insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int J Environ Res Public Health. 2022;19(14):8577.
- Ford BR, Vignali PDA, Rittenhouse NL, et al. Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. Sci Immunol. 2022;7(74). 10.1126/sciimmunol.abj9123.
- Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–495.
- Bogdanovich S, Kim Y, Mizutani T, et al. Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct Target Ther. 2016;1.
- A study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression - full text View. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04296890.
- A Study of STRO-002, an anti-folate receptor alpha antibody drug conjugate, in combination with bevacizumab in epithelial ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT05200364.
- A study to evaluate the safety, tolerability, and efficacy of morab-202 (herein referred to as farletuzumab ecteribulin), a folate receptor alpha (fra)-targeting antibody-drug conjugate (adc) in participants with selected tumor types - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04300556?term=Farletuzumab+ecteribulin&draw=2&rank=1.
- A study of ABBV-428, an immunotherapy, in subjects with advanced solid tumors - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT02955251.
- Bevacizumab and anetumab ravtansine or paclitaxel in treating patients with refractory ovarian, fallopian tube, or primary peritoneal cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03587311?term=Anetumab+Ravtansine&cond=Ovarian+Cancer&draw=2&rank=2.
- A Study of BMS-986148 in patients with select advanced solid tumors - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT02341625.
- Study of REGN4018 administered alone or in combination with cemiplimab in adult patients with recurrent ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03564340?term=REGN4018&draw=2&rank=1.
- Study of REGN5668 administered in combination with cemiplimab or regn4018 in adult women with recurrent ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04590326?term=REGN4018&draw=2&rank=2.
- Oregovomab plus chemo in newly diagnosed patients with advanced epithelial ovarian cancer following optimal debulking surgery - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT04498117.
- Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in participants with high-grade serous ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04907968?term=Upifitamab+Rilsodotin+%28UpRi%29+%28XMT-1536%29&draw=2&rank=1.
- First-in-Human study of XMT-1536 in cancers likely to express NaPi2b - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03319628?term=Upifitamab+Rilsodotin+%28UpRi%29+%28XMT-1536%29&draw=2&rank=2.
- First-in-Human study of XMT-1592 in patients with ovarian cancer and NSCLC likely to express NaPi2b - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04396340?term=XMT-1592&cond=Ovarian+Cancer&draw=2&rank=1.
- A study of Zilovertamab Vedotin (MK-2140) (VLS-101) in participants with solid tumors (MK-2140-002) - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04504916?term=Zilovertamab+Vedotin&cond=Ovarian+Cancer&draw=2&rank=1.
- Paclitaxel and Bevacizumab with or without emactuzumab in treating patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT02923739?term=Emactuzumab&cond=Ovarian+Cancer&draw=2&rank=1.
- A study of PF-06647020 for adult patients with advanced solid tumors - full text view [Internet]. ClinicalTrials.gov. [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02222922.
- A study to evaluate rucaparib in combination with other anticancer agents in patients with a solid tumor (SEASTAR) - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03992131?term=Sacituzumab+Govitecan&cond=Ovarian+Cancer&draw=2&rank=1.
- A study of navicixizumab monotherapy or in combination in patients with select advanced solid tumors - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT05453825?term=Navicixizumab&draw=2&rank=1.
- A study of navicixizumab in patients with platinum resistant ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT05043402?term=Navicixizumab&draw=2&rank=2.
- Tisotumab Vedotin ( HuMax®-TF-ADC) Safety study in patients with solid tumors - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT02552121?term=Tisotumab+Vedotin&cond=Ovary+Cancer&draw=2&rank=2
- Etigilimab and Nivolumab for the treatment of platinum-resistant recurrent clear cell ovarian, primary peritoneal, or fallopian tube cancer - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT05026606?term=Etigilimab&cond=ovarian+cancer&draw=2&rank=1.
- Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT01611558?term=Ipilimumab&cond=Ovarian+Cancer&draw=2&rank=1.
- Durvalumab and tremelimumab in treating participants with recurrent or refractory ovarian, primary peritoneal, or fallopian tube cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03026062?term=Tremelimumab&cond=Ovarian+Cancer&draw=2&rank=4.
- A study of avelumab in combination with other cancer immunotherapies in advanced malignancies (JAVELIN Medley) - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT02554812?term=Utomilumab&cond=Ovarian+Cancer&draw=2&rank=3
- Camrelizumab /Apatinib for recurrent platinum-resistant ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04068974.
- A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer - Full Text View. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03602859?term=Dostarlimab&cond=Ovarian+Cancer&draw=2&rank
- Nivolumab with or without ipilimumab in treating patients with persistent or recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://www.clinicaltrials.gov/ct2/show/NCT02498600.
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) - Full Text View. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT05116189.
- Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT05044871?term=Tislelizumab&cond=Ovarian+Cancer&draw=2&rank
- Phase 1/2 clinical trial of CP-506 (HAP) in monotherapy or with carboplatin or ici - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT04954599?term=Cemiplimab&cond=Ovarian+Cancer&draw=2&rank=3.
- A study of atezolizumab versus placebo in combination with paclitaxel, carboplatin, and bevacizumab in participants with newly-diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT03038100.
- Maintenance treatment with bevacizumab and atezolizumab for ovarian cancer - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04510584.
- Continued access study for participants deriving benefit in pfizer-sponsored avelumab parent studies that are closing - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT05059522?term=Avelumab&cond=Ovarian+cancer+AND+%22Ovarian+Epithelial+Cancer%22&cntry=US&draw=2&rank=10.
- Matched paired pharmacodynamics and feasibility study of durvalumab in combination with chemotherapy in frontline ovarian cancer (N-Dur) full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://www.clinicaltrials.gov/ct2/show/NCT02726997.
- Olaparib, Durvalumab and UV1 in relapsed ovarian cancer full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT04742075.
- A study of vanucizumab (RO5520985) alone or in combination with atezolizumab in participants with locally advanced or metastatic solid tumors - full text view. ClinicalTrials.gov. cited 2022 Jul 15]. Available from 2022 Jul 15: https://clinicaltrials.gov/ct2/show/NCT01688206.
- Dose finding study of BI 836880 in patients with solid tumors - full text view. ClinicalTrials.gov. cited 2022 Oct 7]. Available from 2022 Oct 7: https://clinicaltrials.gov/ct2/show/NCT02674152.
- Weekly BI 836880 in patients with advanced solid tumors full text view. [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02689505
- Redpath NT, Xu Y, Wilson NJ, et al. Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor a1. Biochem J. 2013;451(2):165–175.
- Gui X, Deng M, Song H, et al. Disrupting LILRB4/APOE Interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol Res. 2019;7(8):1244–1257.
- Yu Y, Lee P, Ke Y, et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE. 2010;5(2):e9072.
- Zhao P, Xu Y, Jiang -L-L, et al. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol Neurodegener. 2022;17(1):44.
- Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5.
- Bindon CI, Hale G, Brüggemann M, et al. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988;168(1):127–142.
- Roopenian A, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–725.
- Kinder M, Greenplate AR, Strohl WR, et al. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. mAbs. 2015;7(3):494–504.
- Wilkinson I, Anderson S, Fry J, et al. Fc-engineered antibodies with immune effector functions completely abolished. PLOS ONE. 2021;16(12):e0260954.
- Xie K, Xie, Hinton X, et al., Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021. 595(7869): 718–723.
- Nahta, Hung, Esteva, et al. The HER-2-Targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343–2346.
- Wang D, Dong, Bi L, et al. Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice. Target Oncol. 2010;5(4):237–243.
- Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer - PubMed. N Engl J Med. 2009;360(6):563–572.
- Luke JJ, Barlesi F, Chung K, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2):e002015.
- Chen Y, Xu Y. Pharmacokinetics of Bispecific Antibody. Current Pharmacol Rep. 2017;3(3):126–137.
- Datta-Mannan A, Croy JE, Schirtzinger L, et al. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. mAbs. 2016;8.
- Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy - PubMed. Annu Rev Med. 2013;64.
- Fu Z, Li, Li S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):1–25.
- Manzano A, Ocaña A. Antibody-drug conjugates: a promising novel therapy for the treatment of ovarian cancer. Cancers (Basel). 2020;12.
- Birrer MJ, Betella I, Martin LP, et al. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24.
- A study to assess the efficacy and safety of farletuzumab (MORAb 003) in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (pld) in participants with low ca125 platinum-sensitive ovarian cancer - full text view [Internet]. ClinicalTrials.gov. [Internet]. [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02289950.
- Vergote I, Armstrong D, Scambia G, et al. A randomized, double-blind, placebo-controlled, phase iii study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J clin oncol. 2016;34(19):2271–2278.
- Eisai presents new findings for antibody drug conjugate farletuzumab ecteribulin at 2022 ASCO annual meeting. [Internet]. Eisai Co., Ltd. cited 2022 Jul 14. Available from.:. https://www.eisai.com/news/2022/news202245.html
- Matulonis UA, Oaknin A, Pignata S, et al., Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRa) expression: characterization of antitumor activity in the SORAYA study. J clin oncol. 2022. 40(16_suppl): 5512.
- ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer [Internet]. ImmunoGen, Inc. cited 2022 Jul 14]. Available from 2022 Jul 14: https://investor.immunogen.com/news-releases/news-release-details/immunogen-submits-biologics-license-application-us-food-and-drug.
- ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review [Internet]. ImmunoGen, Inc. cited 2022 Jul 14]. Available from 2022 Jul 14: https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-acceptance-biologics-license-application.
- Nurgalieva AK, Popov VE, Skripova VS, et al. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. Biochem Biophys Rep. 2021;28:101104.
- Richardson DL, Hamilton EP, Oaknin A, et al. Uplift (ENGOT-ov67): a pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. J clin oncol. 2021;39(15_suppl). 5607
- Gerber I, Infante, Gordon JR, et al. Phase I a Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–small cell lung cancer and platinum-Resistant ovarian cancer. Clin Cancer Res. 2020;26(2):364–372.
- Vlasenkova R, Nurgalieva A, Akberova N, et al. Characterization of SLC34A2 as a potential prognostic marker of oncological diseases. Biomolecules. 2021;12(1):11.
- Rottey C, Clarke, Aung J, et al. Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with Advanced Solid Tumors. Clin Cancer Res. 2022;28(1):95–105.
- Theunissen C, Cai, Bhatti AG, et al. Treating tissue factor–positive cancers with antibody–drug conjugates that do not affect blood clotting. Mol Cancer Ther. 2018;17(11):2412–2426.
- A study of weekly tisotumab vedotin for patients with platinum-resistant ovarian cancer with safety run-in (innovaTV 208) full text view [Internet]. ClinicalTrials.gov. [Internet] [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03657043.
- Perrone E, Lopez S, Zeybek B, et al. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Front Oncol. 2020;10:10.
- Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer,Version 2.2020,NCCN Clinical Practice Guidelines in Oncology. J National Compr Cancer Network. 2021;19(2):191–226.
- Ovarian Epithelial, Fallopian tube, and primary peritoneal cancer treatment (PDQ®)–health professional version [Internet]. National Cancer Institute. [cited 2022 Jul 15]. Available from: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq.
- Zhou J, S-G W, Wang J, et al. The effect of histological subtypes on outcomes of stage IV epithelial ovarian cancer. Front Oncol. 2018;8:8.
- Ushijima K. Treatment for recurrent ovarian cancer—At first relapse. J Oncol. 2010;2010:1–7.
- Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393.
- Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by maintenance durvalumab, bevacizumab and olaparib treatment in advanced ovarian cancer patients - Full text view [Internet]. ClinicalTrials.gov. [cited 2022 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT03737643.
- Banerjee S, Gonzalez-Martin A, Harter P, et al. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open. 2020;5(6):e001110.
- McMullen M, Karakasis K, Madariaga A, et al. Overcoming Platinum and PARP-inhibitor resistance in ovarian cancer. Cancers (Basel). 2020;12.
- Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57–70.
- Semenza, Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732.
- Weidemann J, Johnson RS. Biology of HIF-1a. Cell Death Differ. 2008;15(4):621–627.
- Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–4613.
- Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab. Oncologist. 2010;15.
- Itatani Y, Kawada K, Yamamoto T, et al. Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway. Int J Mol Sci. 2018;19(4):1232.
- Horowitz M, Esakov E, Rose P, et al. Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity. Ann Transl Med. 2020;8(14):905.
- Liu Z-J, Shirakawa T, Li Y, et al. Regulation of notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating Arteriogenesis and Angiogenesis. Mol Cell Biol. 2003;23.
- Gridley T Notch signaling in vascular development and physiology - PubMed. Development (Cambridge, England). 2007;134.
- Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:3219–3224.
- Noguera-Troise D, Daly, Papadopoulos C, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032–1037.
- Goel S, Duda DG, Xu L, et al. Normalization of the Vasculature for Treatment of Cancer and Other Diseases. Physiol Rev. 2011;91(3):1071–1121.
- Avastin (bevacizumab) [Information]. U.S. Food and drug administration. [cited 2022 Jul 15]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/avastin-bevacizumab-information.
- FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers. U.S. Food and Drug Administration. [cited 2022 Jul 15]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary.
- Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial - PubMed. Journal of clinical oncology official journal of the American Society of Clinical Oncology 2014;32.
- Liu S, Kasherman L, Fazelzad R, et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2021;161(2):601–612.
- Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016;27:i33–i39.
- Helali W, Wong, Choi CHL, et al., A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. Sci Rep. 2022. 12(1): 1–17.
- Goel S, Wong AH-K, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486–a006486.
- Haibe Y, Kreidieh M, Hajj HE, et al. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol. 2020;10.
- Ghose A, Gullapalli SVN, Chohan N, et al. Applications of Proteomics in Ovarian Cancer: dawn of a New Era. Proteomes. 2022;10(2):16.
- Koskas M, Chereau E, Ballester M, et al. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer - PubMed. Anticancer Res. 2010;30.
- Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182.
- Nejad E, Najafgholian R, Shi G, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):1–26.
- UniProt [Internet]. cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.uniprot.org/uniprot/O43866.
- Aran G, Sanjurjo L, Bárcena C, et al. CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78) - PubMed. FASEB journal official publication of the Federation of American Societies for Experimental Biology 2018;32:3878–3891.
- LaFargue CJ, Amero P, Noh K, et al. Overcoming adaptive resistance to anti-vegf therapy by targeting CD5L. Nature Communications. 2022; •Important paper highlighting the development of therapeutics to overcome adaptive resistance to anti; •Important paper highlighting the development of therapeutics to overcome adaptive resistance to antiVEGF therapy by targeting CD5L.
- UniProt [Internet]. cited 2022 Jul 14]. Available from 2022 Jul 14: https://www.uniprot.org/uniprot/Q8IUX8.
- Yeung G, Mulero JJ, Berntsen RP, et al. Cloning of a novel epidermal growth factor repeat containing gene EGFL6: expressed in tumor and fetal tissues - PubMed. Genomics. 1999;57(1):62.
- von Pawel J, Spigel DR, Ervin T, et al. Randomized Phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung cancer. Oncologist. 2018;23(6):654–e58.
- Bai S, Ingram P, Chen Y-C, et al. EGFL6 regulates the asymmetric division, maintenance, and metastasis of aldh+ ovarian cancer cells. Cancer Res. 2016;76(21):6396–6409.
- Noh K, Mangala LS, Han H-D, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017;21(10):2785–2795.
- An, Du F, Du Y, Fan X, et al., EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. 2018. 38(12): 2123–2134.
- UniProt [Internet]. [cited 2022 Jul 15]. Available from: https://www.uniprot.org/uniprot/Q1L6U9.
- Pei X, Sun Q, Zhang Y, et al. PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2 - PubMed. Journal of immunology (Baltimore, Md1950). 2014;192:1878–1886.
- Pei X, Zheng D, She S, et al. Elevated expression levels of PC3-secreted microprotein (PSMP) in prostate cancer associated with increased xenograft growth and modification of immune-related microenvironment. Front Oncol. 2019;9. 10.3389/fonc.2019.00724.
- Nam RK, Reeves JR, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis - PubMed. J Urol. 2006;175(4):1291–1297.
- Valtonen-André C, Bjartell A, Hellsten R, et al. A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue - PubMed. Biol Chem. 2007;388.
- Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264.
- Pei Z, Zheng, She D, et al. The PSMP-CCR2 interactions trigger monocyte/macrophage-dependent colitis. Sci Rep. 2017;7(1):1–14.
- She S, Wu X, Zheng D, et al. PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target. J Hepatol. 2020;72(3):506–518.
- Pienta KJ, Machiels J-P, Schrijvers D, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer - PubMed. Invest New Drugs. 2013;31.
- Mitamura P, Pradeep, McGuire S, et al., Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. 2017. 37(6): 722–731.